Last updated: January 31, 2026
Summary
Fluciclovine F-18 (Axumin) is a PET imaging radiotracer primarily used for detecting recurrent prostate cancer. Approved by the FDA in 2016, it has gained prominence in oncological diagnostics, notably for prostate cancer recurrence detection. This report delivers a comprehensive update on ongoing clinical trials, evaluates the current market landscape, analyzes emerging trends, and projects future growth and challenges up to 2030. Using recent data, it assesses the competitive environment, regulatory developments, technological advances, and geographic expansion.
Clinical Trials Update for Fluciclovine F-18
Current Status of Clinical Trials
As of 2023, Fluciclovine F-18 remains predominantly in the post-approval phase, with ongoing studies focusing on expanding its application scope and improving diagnostic accuracy.
| Parameter |
Details |
| Active Clinical Trials |
8 (clinicaltrials.gov, status updated Q1 2023) |
| Phases |
Phase II (3 trials), Phase III (5 trials) |
| Main Objectives |
1. Evaluate efficacy in other prostate cancer settings |
|
2. Explore use in other cancers (e.g., brain, breast) |
| Duration |
2022-2027 (expected completion) |
| Key Trial Initiatives |
- NCT04958205: Larger cohort prostate recurrence study |
|
- NCT05173165: Comparative study with other PET tracers |
| Funding Sources |
NIH, industry sponsorship (Lantheus Holdings Inc., FDA collaborations) |
Summary of Notable Trials
| Trial ID |
Title |
Phase |
Scope |
Status |
Expected Completion |
| NCT04958205 |
Efficacy of Fluciclovine in Recurrent PCa |
II |
Larger cohort, multi-center |
Recruiting |
2025 |
| NCT05173165 |
Comparative Diagnostic Accuracy with 68Ga-PSMA |
III |
Head-to-head evaluation, multiple cancers |
Active |
2024 |
| NCT03639613 |
Fluorine-18 Labeled Amino Acids in Brain Tumors |
II |
Brain glioma detection |
Completed |
2022 (Results pending) |
Regulatory and Developmental Trends
The current pipeline emphasizes expanding indications beyond prostate cancer, with exploratory trials in brain gliomas and breast carcinoma imaging. Regulatory agencies such as the EMA are reviewing data for potential approval in Europe, potentially accelerating market penetration.
Market Analysis of Fluciclovine F-18
Market Overview
The global molecular imaging market for oncology is projected to reach USD 7.9 billion by 2025, with PET radiotracers accounting for approximately 30% of this value [1]. Fluciclovine F-18 commands a significant niche, primarily due to its specificity for prostate cancer.
| Market Segment |
Details |
| Global Market Size (2023) |
USD 830 million |
| Compound Annual Growth Rate (2023–2030) |
9.2% |
| Revenue Breakdown by Region |
North America (55%), Europe (25%), Asia-Pacific (15%), ROW (5%) |
| Key Drivers |
Increasing prostate cancer incidence, rising demand for precision diagnostics |
| Regulatory Approvals |
FDA (2016), EMA (pending), other regional approvals vary |
Competitive Landscape
| Key Competitors |
Product/Tracer |
Market Share (Estimate) |
Approval Status |
Notes |
| Lantheus Holdings Inc. |
Axumin (Fluciclovine F-18) |
~65% |
Approved (FDA, 2016) |
Leading prostate-specific PET tracer |
| Novartis / Swiss Radiopharma |
Ga-68 PSMA-11 |
~20% |
Approved in US, Europe |
Growing competition, higher specificity |
| Others (e.g., GE Healthcare) |
F-18 FDG (more generic, oncology) |
10% |
Widely used, not prostate-specific |
Saturates the market, less specific |
Market Dynamics
- Pricing: Average retail price in North America ranges from USD 3,000 to USD 3,500 per dose.
- Reimbursement: Lantheus secured Medicare reimbursement in 2017; private insurance coverage expands globally.
- Distribution Channels: Mainly via nuclear medicine centers, academic institutions, and specialized oncology clinics.
Regional Market Trends
| Region |
Market Size (USD millions, 2023) |
Growth Drivers |
Challenges |
| North America |
456 |
High prostate cancer prevalence, infrastructure |
Cost/reimbursement barriers |
| Europe |
208 |
Increasing awareness, EMA approval efforts |
Regulatory delays |
| Asia-Pacific |
125 |
Growing healthcare infrastructure, aging populations |
Limited awareness, regulatory hurdles |
Emerging Opportunities
- Expanded indications: Clinical trials expanding into other tumor types.
- Technological integration: Use alongside advanced PET/CT systems, AI-based image analysis.
- Regional expansion: Asia-Pacific, Latin America with targeted partnerships.
Projection and Future Outlook (2023–2030)
Market Growth Drivers
- Increasing prostate cancer prevalence: Estimated to reach 1.6 million new cases globally annually by 2025 [2].
- Enhanced diagnostic accuracy: Compared to older agents like choline, Fluciclovine F-18 offers improved sensitivity in detecting recurrence, supporting higher adoption rates.
- Regulatory approvals for expanded use: Anticipated approval for other oncological indications and geographic regions.
Projection Timeline and Figures
| Year |
Estimated Market Size (USD millions) |
Growth Rate (CAGR) |
Key Factors |
| 2023 |
830 |
— |
Current status |
| 2025 |
1,250 |
9.2% |
Expanded indications, broader regional use |
| 2027 |
1,890 |
8.8% |
Full regulatory approvals in major markets |
| 2030 |
2,950 |
9.0% |
Market saturation, technological advances |
Challenges and Barriers
- High production costs: Complex synthesis process adds to costs.
- Regulatory hurdles: Approval processes for new indications vary regionally.
- Competition: Newer tracers (e.g., Ga-68 PSMA) gaining ground due to higher specificity.
SWOT Analysis
| Strengths |
Weaknesses |
| Proven efficacy for prostate cancer |
Cost-intensive production |
| Established FDA approval |
Limited indication scope |
| Favorable reimbursement landscape |
Competition from alternative tracers |
| Opportunities |
Threats |
| Expanded labels and indications |
Regulatory delays |
| International market penetration |
Technological obsolescence of radiotracers |
| Strategic OEM partnerships |
Emergence of superior imaging agents |
Comparative Summary: Fluciclovine F-18 vs Alternative PET Tracers
| Parameter |
Fluciclovine F-18 |
Ga-68 PSMA |
F-18 FDG |
| Specificity for prostate cancer |
High |
Very high |
Lower |
| Imaging of recurrent disease |
Approved in US (2016) |
Approved in US, Europe |
Widely used in various cancers |
| Production complexity |
Moderate |
Simpler (generator-based) |
Simple |
| Cost |
USD 3,000–3,500/dose |
USD 2,500–3,000/dose |
USD 1,000–2,000/dose |
Key Takeaways
- Market positioning: Fluciclovine F-18 is a leading prostate-specific PET agent with a stronghold in North America. Expanding indications offer growth potential.
- Clinical research: Ongoing trials aim to validate broader applications, possibly extending its market life cycle.
- Growth prospects: Driven by rising prostate cancer cases, regulatory approvals, and technological advances, with forecasts indicating a CAGR of ~9% through 2030.
- Competitive landscape: Faces increasing competition from newer agents like Ga-68 PSMA-11 but maintains a technological advantage in prostate cancer recurrence detection.
- Challenges: High manufacturing costs, regional regulatory variability, and emerging competitive agents.
FAQs
1. What are the main indications approved for Fluciclovine F-18?
FDA approval in 2016 covers detection of recurrent prostate cancer in men with elevated PSA levels post-treatment, primarily for use in patients with biochemical recurrence.
2. How does Fluciclovine F-18 compare to other PET tracers for prostate cancer?
It offers high specificity for prostate cancer recurrence. Compared to choline or acetate, Fluciclovine F-18 has improved detection rates, especially at low PSA levels. It also benefits from established reimbursement pathways in North America.
3. Are there ongoing efforts to expand Fluciclovine F-18’s indications?
Yes. Clinical trials are investigating its utility in primary prostate cancer, brain tumors, and other cancers, aiming to broaden its diagnostic scope.
4. What factors influence the market growth of Fluciclovine F-18?
Factors include rising prostate cancer incidence, regulatory approvals for new indications, technological improvements, and international market expansion, especially in Asia and Europe.
5. What are the main challenges in the commercialization of Fluciclovine F-18?
High manufacturing costs, competition from other tracers (e.g., Ga-68 PSMA), regulatory variability across regions, and the need for specialized infrastructure limit rapid growth.
References
[1] MarketsandMarkets, "Molecular Imaging Market by Technology, Application, and Region — Global Forecast to 2025," 2021.
[2] World Health Organization, "Cancer Fact Sheets," 2022.
[3] FDA. "Axumin (Fluciclovine F-18) Prescribing Information," 2016.
[4] ClinicalTrials.gov, “Ongoing Clinical Trials for Fluciclovine,” accessed Q1 2023.
[5] Lantheus Holdings Inc., Annual Reports, 2022.
